Affidea continues its expansion policy in Spain with the acquisition and opening of new centers.

  • During 2021, Europe's largest provider of diagnostic imaging, outpatient and oncology care services has completed its network in Spain, reaching 40 centers, as well as renewing its equipment and achieving nuclear medicine accreditation in three of its centers.

  • In 2022, new centers will be opened in autonomous communities where the company does not yet operate, offering more specialized care to patients and improving their experience and access to healthcare.

Madrid, February 7, 2022-. Affidea, the largest European provider of diagnostic imaging, outpatient and oncology care services, closed the year 2021 in Spain in a process of expansion, after the opening of two new centers in Somosaguas (Madrid) and Hospitalet (Barcelona), the acquisition of Medicentro, an outpatient healthcare provider with three centers in the southwest of Madrid, and of Clínica Gamma, accredited in nuclear medicine by the European Accreditation of the Nuclear Medicine Department.

Thus, there are now three Affidea centers (Clínica Gamma, PET Jove and PET-CT La Milagrosa) with this accreditation in nuclear medicine, which ensures correct daily practice, a continuous offer of consistent services, permanent uniformity and confidence in the results, availability of technical and human capabilities and international recognition. The PET Jove (Gijón) and PET-TAC La Milagrosa (Madrid) centers also have the EARL (ResEARch for Life) Accreditation, issued by the European Association of Nuclear Medicine (EANM) to promote research and multicenter nuclear medicine.